BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 15, 2026
Breaking News: New research identifies EBV antigen targets for MS therapiesBreaking News: New research identifies EBV antigen targets for MS therapiesBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric RSS Feed RSS

Parkinson's disease illustration showing neurons containing alpha-synuclein
Neurology/psychiatric

Grant supports Lario’s evaluation of Cav2.3 calcium channel inhibitors for Parkinson’s disease

July 22, 2024
Lario Therapeutics Ltd. has been awarded a $6 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
Read More
Neurology/psychiatric

Hangzhou Zhongmei Huadong Pharmaceutical discovers new STING antagonists

July 19, 2024
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described oxime-containing compounds acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, transplant rejection and neurodegeneration, among others.
Read More
Neurology/psychiatric

Merck Sharp & Dohme describes new NLRP3 inflammasome inhibitors

July 19, 2024
Merck Sharp & Dohme LLC has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune diseases, Alzheimer’s disease and Parkinson’s disease, among others.
Read More
Nervous system illustration
Neurology/psychiatric

Synaptogenix’s PUFA analogues for spinal cord injury

July 19, 2024
Synaptogenix Inc. has entered into a new collaboration agreement with LSU Health New Orleans’ Neuroscience Center of Excellence for preclinical testing of the company’s polyunsaturated fatty acid (PUFA) analogues.
Read More
Neurology/psychiatric

MK2 inhibitor protects murine microglial cells from neuroinflammation

July 19, 2024
Cigarette smoke, the main cause of chronic obstructive lung disease, is considered a significant contributor of neuroinflammation, potentially leading to cognitive impairment and neurodegeneration. About 61% of individuals with chronic obstructive pulmonary disease have neurocognitive dysfunction.
Read More
Fruit fly muscles showing how well mitochondria produce energy
Infection

Infection and brain neuroinflammation weaken muscles

July 19, 2024
By Mar de Miguel
Muscle fatigue associated with brain inflammation could be prevented by modulating certain cytokines. Researchers at Washington University in St. Louis (WUSTL) have studied inflammation in the CNS in infection models of Escherichia coli, SARS-CoV-2 and amyloid-β toxicity, unveiling its impact on motor function, the role of IL-6 in this process and how to mitigate it in chronic disease.
Read More
3D cross-section illustration of muscle anatomy
Musculoskeletal

FDA approves IND for Myopaxon in Duchenne muscular dystrophy

July 18, 2024
Myogenica Inc., a University of Minnesota startup company, has obtained IND approval from the FDA for Myopaxon, an induced pluripotent stem cell (iPSC)-derived muscle stem cell product to regenerate skeletal muscle. A planned study will evaluate intramuscular injections of Myopaxon in non-ambulatory adult patients with Duchenne muscular dystrophy.
Read More
Biomarkers

AJAP1 de novo variants tied to epilepsy pathogenesis, study finds

July 17, 2024
Adherens junction-associated protein 1 (AJAP1) is a transmembrane protein that inhibits tumor cell migration and is a susceptibility gene for migraine. Recent hypotheses have pointed toward the potential involvement of AJAP1 in epilepsy and other neurological disorders.
Read More
Neurology/psychiatric

University of Copenhagen discovers new PSD-95 inhibitors for neuropathic pain

July 16, 2024
University of Copenhagen has described cyclic peptides acting as postsynaptic density-95 (PSD-95) protein inhibitors reported to be useful for the treatment of neuropathic pain.
Read More
Neuron
Neurology/psychiatric

Artelo’s FABP5 inhibitor cleared to enter clinic for chemotherapy-induced peripheral neuropathy

July 16, 2024
Artelo Biosciences Inc.’s IND application for ART-26.12, for the treatment of chemotherapy-induced peripheral neuropathy, has been granted clearance by the FDA allowing the company to initiate a first-in-human phase I study. Results are expected in the first half of next year.
Read More
Previous 1 2 … 117 118 119 120 121 122 123 124 125 … 2813 2814 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 14, 2026.
  • AI-generated  illustration of a neuron with tau protein aggregation

    AAIC 2026: Age of amyloid is being joined by time of tau

    BioWorld
    The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
  • Modius Spero wearable neuromodulation device

    Neurovalens granted FDA approval for PTSD therapy for US veterans

    BioWorld
    Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 14, 2026
  • Senior medical exam

    Celia trial: data strong, analysts skeptical

    BioWorld
    Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing